---
title: "Atara Biotherapeutics files initial beneficial ownership statement for interim CFO Kevin Sarney"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291840045.md"
description: "Atara Biotherapeutics filed a Form 3 with the SEC, disclosing initial beneficial ownership for Kevin G. Sarney in his role as interim CFO. The filing was published via EDGAR on July 6, 2026."
datetime: "2026-07-06T20:15:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291840045.md)
  - [en](https://longbridge.com/en/news/291840045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291840045.md)
generator: "portal-rs"
---

# Atara Biotherapeutics files initial beneficial ownership statement for interim CFO Kevin Sarney

-   Atara Biotherapeutics filed a Form 3 naming Kevin G. Sarney as interim CFO. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000905148-26-003168), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ATRA.US](https://longbridge.com/en/quote/ATRA.US.md)

## Related News & Research

- [Atara Biotherapeutics director Brian Cherry acquires 104,166 common shares for $999,993.60](https://longbridge.com/en/news/298079643.md)
- [Independent Director of Atara Biotherapeutics Picks Up 272% More Stock](https://longbridge.com/en/news/298137689.md)
- [Atara Biotherapeutics Director Purchased Shares Worth Over $999K](https://longbridge.com/en/news/298080002.md)
- [Outlook Therapeutics CFO Kevin Michael Lundquist files initial beneficial ownership statement](https://longbridge.com/en/news/297827378.md)
- [RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results](https://longbridge.com/en/news/298139566.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**